Delivery Order SPE2DB22D9239-SPE2DB25FDL68
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $11,353.77 by the Defense Logistics Agency on August 28, 2025, for the supply of Lenvima 14 mg daily dose tablets in quantities of 60 units. The contract carries an ultimate completion date of September 19, 2025, and does not utilize a set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $11,353.77 by the Defense Logistics Agency on August 22, 2025, for the supply of Lenvima 8 mg daily dose tablets (60-count). This firm fixed-price delivery order is scheduled for completion by September 15, 2025, with performance taking place at the vendor's Park Ridge location. The award was made without a set-aside designation, reflecting...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on September 10, 2025, by the Defense Logistics Agency for the supply of Lenvima 14 mg daily dose medication in quantities of 60 units. This firm fixed-price delivery order, valued at $11,353.77, is scheduled for completion by October 1, 2025, with no set-aside designation applied. The award represents a continuation of DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 8 mg daily dose tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $11,353.77, was awarded on September 10, 2025, with an ultimate completion date of October 1, 2025. The contract contains no set-aside designation, allowing DMS Pharmaceutical Group to compete...
- The U.S. Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. for LENVIMA 20 mg daily dose (60-count supply) valued at $11,353.77 on August 21, 2025, with completion expected by September 12, 2025. This firm fixed-price delivery order was awarded without set-aside designation to the Park Ridge, Illinois-based woman-owned small business pharmaceutical wholesaler. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for LENVIMA 8 mg daily dose tablets (60-count supply) with a ceiling value of $11,353.77. This firm fixed-price delivery order, awarded on August 28, 2025, with an ultimate completion date of September 19, 2025, represents a procurement of a specialized oncology medication. The contract carries no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $11,353.77 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 10 mg daily dose tablets (30-count packaging). This firm fixed-price delivery order was issued on September 10, 2025, with an ultimate completion date of October 1, 2025, and carries no set-aside designation. DMS Pharmaceutical Group is performing this work from its Park Ridge...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,353.77 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 18 mg daily dose medication in a 90-day supply. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS...
- The U.S. Defense Logistics Agency awarded a Firm Fixed Price Delivery Order to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business, to provide Lenvima 10 mg daily dose 30s. The $10,662.16 contract has a completion date of March 6, 2024. DMS Pharmaceutical Group is an experienced federal contractor providing a wide range of pharmaceutical products and medical supplies to the Department of Defense and Department of Veterans Affairs under various prime vendor contracts,...
- The Defense Logistics Agency awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide the pharmaceutical product LENVIMA 10 MG DAILY DOSE 30S. The contract has a potential value of $10,662.16 and a completion date of January 17, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a wide range of pharmaceutical and medical supplies to the federal government, primarily the Department of Defense,...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB25FDL68Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $11,353.77 by the Defense Logistics Agency on September 9, 2025, for the supply of Lenvima 10 mg daily dose tablets (30-count packaging). The contract carries an ultimate completion date of September 30, 2025, and includes no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion single-award vehicle valid through November 2026 that authorizes the issuance of firm fixed-price orders for comprehensive pharmaceutical and medical supply products. DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, providing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities and military installations nationwide. The company's robust portfolio of federal contract awards demonstrates consistent capability in delivering specialized pharmaceutical products, including oncology treatments and other prescription medications, to support the medical supply requirements of military health facilities across the globe. Lenvima, a targeted cancer therapy medication, aligns with the company's established track record of supplying advanced pharmaceutical treatments to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 9/9/25 |